rdf:type |
|
lifeskim:mentions |
|
pubmed:dateCreated |
2009-11-16
|
pubmed:abstractText |
There is accumulating data on the clinical benefit of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer in postmenopausal women. The Breast International Group (BIG) 1-98 study is a randomized, phase 3, double-blind trial comparing four adjuvant endocrine treatments of 5 years duration in postmenopausal women with hormone-receptor-positive breast cancer: letrozole or tamoxifen monotherapy, sequential treatment with tamoxifen followed by letrozole, or vice versa. This article summarizes data presented at the 2009 St. Gallen early breast cancer conference: an update on the monotherapy arms of the BIG 1-98 study, and results from the sequential treatment arms. Implications for daily practice from BIG 1-98 and from other adjuvant trials will be discussed.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Aromatase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Triazoles,
http://linkedlifedata.com/resource/pubmed/chemical/letrozole
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1532-3080
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
18 Suppl 3
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
S78-82
|
pubmed:meshHeading |
pubmed-meshheading:19914548-Antineoplastic Agents, Hormonal,
pubmed-meshheading:19914548-Aromatase Inhibitors,
pubmed-meshheading:19914548-Breast Neoplasms,
pubmed-meshheading:19914548-Chemotherapy, Adjuvant,
pubmed-meshheading:19914548-Disease-Free Survival,
pubmed-meshheading:19914548-Double-Blind Method,
pubmed-meshheading:19914548-Drug Administration Schedule,
pubmed-meshheading:19914548-Female,
pubmed-meshheading:19914548-Follow-Up Studies,
pubmed-meshheading:19914548-Humans,
pubmed-meshheading:19914548-Nitriles,
pubmed-meshheading:19914548-Postmenopause,
pubmed-meshheading:19914548-Proportional Hazards Models,
pubmed-meshheading:19914548-Receptors, Estrogen,
pubmed-meshheading:19914548-Receptors, Progesterone,
pubmed-meshheading:19914548-Tamoxifen,
pubmed-meshheading:19914548-Triazoles
|
pubmed:year |
2009
|
pubmed:articleTitle |
Update of the BIG 1-98 Trial: where do we stand?
|
pubmed:affiliation |
Breast Center, Cantonal Hospital, St. Gallen, Switzerland.
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|